Mar 28 |
Inventiva announces the nomination of Andre Turenne as Director
|
Mar 27 |
Inventiva GAAP EPS of -€2.43, revenue of €17.48M
|
Mar 27 |
Inventiva reports its 2023 full-year results
|
Mar 22 |
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
|
Mar 18 |
Inventiva Phase 2 study for MASH drug meets primary endpoint
|
Mar 18 |
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
|
Mar 13 |
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
|
Mar 8 |
Inventiva resumes Phase 3 study for NASH drug, stock up 6%
|
Mar 7 |
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
|
Feb 22 |
Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause
|